Your browser doesn't support javascript.
loading
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.
Baca, Sylvan C; Seo, Ji-Heui; Davidsohn, Matthew P; Fortunato, Brad; Semaan, Karl; Sotudian, Shahabbedin; Lakshminarayanan, Gitanjali; Diossy, Miklos; Qiu, Xintao; El Zarif, Talal; Savignano, Hunter; Canniff, John; Madueke, Ikenna; Saliby, Renee Maria; Zhang, Ziwei; Li, Rong; Jiang, Yijia; Taing, Len; Awad, Mark; Chau, Cindy H; DeCaprio, James A; Figg, William D; Greten, Tim F; Hata, Aaron N; Hodi, F Stephen; Hughes, Melissa E; Ligon, Keith L; Lin, Nancy; Ng, Kimmie; Oser, Matthew G; Meador, Catherine; Parsons, Heather A; Pomerantz, Mark M; Rajan, Arun; Ritz, Jerome; Thakuria, Manisha; Tolaney, Sara M; Wen, Patrick Y; Long, Henry; Berchuck, Jacob E; Szallasi, Zoltan; Choueiri, Toni K; Freedman, Matthew L.
Afiliación
  • Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Seo JH; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Davidsohn MP; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Semaan K; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sotudian S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lakshminarayanan G; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Diossy M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Qiu X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • El Zarif T; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Canniff J; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Madueke I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Saliby RM; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Zhang Z; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Li R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Jiang Y; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Taing L; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.
  • Awad M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Chau CH; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Figg WD; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Greten TF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hata AN; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hughes ME; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ligon KL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lin N; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Oser MG; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Meador C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Parsons HA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Pomerantz MM; Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
  • Rajan A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ritz J; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Thakuria M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Tolaney SM; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Wen PY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Long H; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Berchuck JE; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Szallasi Z; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Freedman ML; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nat Med ; 30(3): 907, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38049623
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos